Breast Fat Grafting After Cancer / Lipomodelling | Cancer clearance and candidacy

The oncologic safety of fat grafting has been questioned, and no reliable studies definitively confirm it in breast cancer patients. For conservative-treatment sequelae, the risk of coincidence with new or recurrent cancer is high, so very strict control is needed. Only patients free of local breast disease are considered eligible, with appropriate clinical and radiological breast evaluation. A suspicious lesion is an absolute contraindication, and lipofilling should not be performed with positive margins or very high relapse risk. Agreement of the radiologist and oncologist in charge is generally required before lipomodelling, and imaging must confirm no suspicious lesions; if doubt, the procedure is deferred or contraindicated.

Early grafting may give faster results and reduce procedures, while delaying allows better blood supply and lets contour deformities appear. In one described protocol, radiotherapy starts 2–3 months after mastectomy for advanced cancers or 6 months for early cancers with risk factors, with one or two fat-grafting sessions 6 weeks after radiotherapy and expander exchange about 3 months later. After lumpectomy, fat grafting can improve contour and radiated skin quality, but radiated defects are challenging and more than one session may be needed. After mastectomy, total reconstruction with fat alone is generally delayed and requires consecutive sessions. Only patients free of local breast disease are considered eligible, with appropriate clinical and radiological evaluation.

The concern is biological, not just technical. Enriched grafts contain more vasculogenic and regenerative cells, and laboratory studies show highly manipulated adipose-derived stem cells can promote breast cancer cell growth through growth-factor pathways in vitro. Neoplastic processes also use angiogenesis and regeneration, so the same properties that aid reconstruction raise theoretical tumorigenic questions. Evidence after cancer remains largely expert experience and clinical series, not broad consensus. Only patients free of local breast disease are considered eligible, and after breast-conserving therapy publications are contradictory about possible relapse risk. Average surgeons generally do not amplify or concentrate these cells; amplified procedures should be under institutional review board-approved protocols.

Whether lipomodelling can be done while taking endocrine therapy must be decided individually with your oncology team. More generally, only patients free of local breast disease are considered eligible, with appropriate clinical and radiological breast evaluation. Agreement of the radiologist and oncologist is generally required before lipomodelling, and breast imaging is repeated one year after the procedure. Evidence for oncological safety comes from expert experience and clinical series, and no international consensus exists yet. Imaging surveillance and oncologist agreement remain important before and after grafting. Your oncology team should guide timing, imaging and follow-up for your case. Dr. Vishal Purohit can discuss these considerations during consultation. No specific method or outcome is implied.

Fat grafting after cancer is generally considered when you are free of local breast disease and have appropriate clinical and radiological evaluation. Studies reviewed here report no significant increase in locoregional or distant recurrence or new cancer after breast fat grafting, though evidence has been limited and mainly expert experience or clinical series. A mutation may raise questions about contralateral breast risk and genetic testing, which are separate from whether grafted fat itself increases recurrence. Both patients with and without prior breast cancer need routine imaging surveillance for life. Radiological changes after grafting are often benign and can be differentiated from cancer recurrence.

Before fat transfer, suspicious findings such as a palpable lump, cyst, major fibrocystic change, calcifications with diagnostic doubt, or an unclear breast pattern should be investigated. Ultrasound is the simplest non-invasive test; mammography or MRI may follow, and biopsy is considered if doubt remains. A senologist, oncologist or GP may be consulted for unclear morphology. Only patients free of local breast disease are considered eligible, and careful preoperative clinical and radiologic clearance is essential. Regular imaging surveillance continues for all patients, and concerning postoperative findings may warrant additional studies. Surgeons remain vigilant to identify recurrence, differentiate it from expected benign post-fat-grafting lesions, and treat it expeditiously. Every palpable lump should be treated as possible cancer until proved otherwise.

Autologous fat grafting can fill contour defects, ease radiation-related skin changes and improve scarring after breast-conserving surgery. For tethered scars, it is combined with a small needle scar release, which helps fat placement, limits later retraction and suits localized scars. It may also improve radiodystrophy changes. Fat grafting is indicated for volume restoration when implant or flap reconstruction is declined or unsuitable, and it is technically less complex than flap harvest and transfer. Only patients free of local breast disease are considered eligible after clinical and imaging evaluation. Because cancer recurrence concerns remain, caution is needed and recurrence risk should be assessed before surgery. Several sessions may be needed, especially after radiation, because some transferred fat does not survive.

Fat grafting uses your own fat and can improve contour and volume without a device, but some fat is absorbed and several sessions may be needed, especially after radiation. It is often used for contour deformities, step-offs, lumpectomy defects, or to enhance flap volume. If donor fat is insufficient or a larger volume is needed, an implant under a flap can add projection, though capsular contracture remains a risk, especially after radiotherapy. A flap may be chosen when more substantial rebuilding is needed. Fat grafting may also improve radiated skin quality, while implants are limited by their fixed dimensions and upper-pole contour abnormalities can persist.

Fat grafting depends on enough harvestable fat and a recipient site that can accept it. Graft volume loss of 40–60% from absorption or tissue death is described, so several sessions may be needed, especially after radiation. If insufficient breast volume is obtained, a small central implant or a secondary flap may be considered. In selected patients with breast cancer-related arm swelling, the swollen arm has been described as a donor site. Donor-site selection, harvesting, processing and delivery technique all influence survival, and recipient compliance and capacity also matter. Multiple sessions are often spaced months apart, and careful preoperative evaluation helps set expectations.